The report “Peritoneal Cancer – Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.
Complete Report Details Available athttps://www.wiseguyreports.com/reports/peritoneal-cancer-pipeline-review-h1-2016 .
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/peritoneal-cancer-pipeline-review-h1-2016 .
Peritoneal Cancer – Companies Involved in Therapeutics Development:
Acetylon Pharmaceuticals, Inc.
Adaptimmune Therapeutics Plc
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advenchen Laboratories, LLC
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Atara Biotherapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Caladrius Biosciences, Inc.
Celldex Therapeutics, Inc.
Cerulean Pharma, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Critical Outcome Technologies Inc.
CTI BioPharma Corp.
Dr. Reddy’s Laboratories Limited
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Ganymed Pharmaceuticals AG
Genor BioPharma Co., Ltd.
Hemispherx Biopharma, Inc.
Innate Pharma S.A.
Johnson & Johnson
Juno Therapeutics Inc.
Kyowa Hakko Kirin Co., Ltd.
Lee’s Pharmaceutical Holdings Limited
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pharma Mar, S.A.
PsiOxus Therapeutics Limited
Quest PharmaTech Inc.
Sanofi Pasteur SA
Shenzen SiBiono GeneTech Co., Ltd.
Synta Pharmaceuticals Corp.
Vascular Biogenics Ltd.
VentiRx Pharmaceuticals, Inc.
– The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
– The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
– The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Get a sample copy at https://www.wiseguyreports.com/sample-request/peritoneal-cancer-pipeline-review-h1-2016 .
P: +44 208 133 9349
M: +1 646 845 9349